Henry Schein (Nasdaq: HSIC ) is expected to report Q4 earnings on Feb. 13. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Henry Schein's revenues will grow 2.6% and EPS will grow 4.3%.
The average estimate for revenue is $2.40 billion. On the bottom line, the average EPS estimate is $1.20.
Last quarter, Henry Schein recorded revenue of $2.23 billion. GAAP reported sales were 5.7% higher than the prior-year quarter's $2.11 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, EPS came in at $1.08. GAAP EPS of $1.08 for Q3 were 9.1% higher than the prior-year quarter's $0.99 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 27.3%, 50 basis points worse than the prior-year quarter. Operating margin was 6.7%, 10 basis points worse than the prior-year quarter. Net margin was 4.3%, 10 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $8.93 billion. The average EPS estimate is $4.37.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 90 members out of 101 rating the stock outperform, and 11 members rating it underperform. Among 34 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 32 give Henry Schein a green thumbs-up, and two give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Henry Schein is hold, with an average price target of $79.53.
Is Henry Schein the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Henry Schein to My Watchlist.